On November 10, 2026, the U.S. Food and Drug Administration (FDA) released a proposed rule to reclassify certain immunohistochemistry (IHC) test systems used with a corresponding approved oncology therapeutic product from the current Class III (Premarket Approval, PMA) to Class II (Special Controls), subjecting them to the 510(k) premarket notification pathway.
This reclassification involves 12 FDA product codes, covering oncology companion diagnostic products as well as related IHC test systems intended to provide information about the benefits or risks of a corresponding approved oncology therapeutic product.
Note that this document is currently a proposed rule and has not yet taken effect. FDA also made clear that such products will not be exempt from 510(k) requirements, and manufacturers will still need to complete the corresponding premarket notification process.
1. Regulatory Overview
The proposed rule concerns 21 CFR Part 864 (Hematology and Pathology Devices). FDA plans to add a new section, 864.1895, establishing classification and regulatory requirements specifically for IHC test systems used with a corresponding approved oncology therapeutic product.
| Item | Details |
|---|---|
| Issuing agency | U.S. Food and Drug Administration (FDA) |
| Document title | Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product |
| Document number | 2026-23005 |
| Docket number | FDA-2026-N-12508 |
| Regulation involved | 21 CFR Part 864 |
| Proposed new section | 21 CFR 864.1895 |
| Document type | Proposed Order (proposed reclassification order) |
| Planned publication date | November 12, 2026 |
| Comment period | 60 days after formal publication |
| Proposed effective date | 30 days after publication of the final rule |
2. Core Change: From Class III (PMA) to Class II (510(k))
The most important change in the proposed rule is the adjustment of the regulatory classification and premarket submission pathway for certain IHC test systems associated with approved oncology therapeutic products.
2.1 Current Regulatory Requirements
At present, the products involved are Class III devices regulated under the PMA (Premarket Approval) pathway.
Before placing such products on the market, manufacturers must submit a PMA application to FDA and complete the corresponding approval process.
2.2 Proposed Regulatory Requirements After Reclassification
If the proposed rule is finalized, the relevant products would be regulated as follows:
- Device classification: Class II;
- Regulatory approach: Special Controls;
- Premarket submission pathway: 510(k);
- 510(k) exemption: not applicable.
In other words, manufacturers would no longer need to apply under the original PMA pathway; instead, they would submit a 510(k) premarket notification and market the product after obtaining FDA clearance.
3. Which Products Are Covered by This Reclassification?
The reclassification does not apply to all immunohistochemistry reagents or pathology test products, but only to specific IHC test systems associated with a corresponding FDA-approved oncology therapeutic product.
According to the proposed rule, covered products mainly share the following characteristics:
1. They are prescription in vitro diagnostic devices (prescription IVDs);
2. They use monoclonal or polyclonal antibodies;
3. They detect protein expression in human clinical specimens using immunohistochemistry techniques;
4. The test results are intended to provide information relevant to a corresponding approved oncology therapeutic product.
FDA divides the covered products into two categories:
Category 1: Companion Diagnostics (CDx)
For these test systems, the information provided is essential for the safe and effective use of the corresponding therapeutic product.
Examples include:
- Identifying patients most likely to benefit from a specific therapeutic product;
- Identifying patients at risk of serious adverse reactions after use of a specific therapeutic product;
- Monitoring therapeutic response so that the treatment regimen can be adjusted;
- Identifying the population in which the therapeutic product has been adequately studied and demonstrated to be safe and effective.
The intended use of such tests is typically specified in the labeling of both the diagnostic device and the corresponding therapeutic product.
Category 2: Non-essential therapy-associated test systems
These products are not a prerequisite for using the corresponding therapeutic product, but they can provide information related to the known benefits or risks of that therapeutic product.
For example, by testing a specific biomarker, they help physicians assess the benefits or risks of the corresponding therapeutic product in a particular patient population.
4. The 12 FDA Product Codes Involved
The proposed rule covers the following 12 product codes:
| No. | FDA Product Code |
|---|---|
| 1 | MVC |
| 2 | NKF |
| 3 | QQT |
| 4 | NQF |
| 5 | PLS |
| 6 | PKW |
| 7 | QUL |
| 8 | QNH |
| 9 | QZJ |
| 10 | SBL |
| 11 | SER |
| 12 | SHF |
FDA proposes to classify all of the above products under the newly established 21 CFR 864.1895.
For existing products, FDA states that the original product codes will generally remain unchanged; future new products will be assigned either an existing product code or a new product code depending on the circumstances.
In addition, FDA found that some previously approved oncology therapy-associated IHC products had been incorrectly linked in the PMA and product classification databases to the existing 864.1860 (immunohistochemistry reagents and kits).
Through this rule, FDA intends to clarify that IHC test systems used with a corresponding approved oncology therapeutic product belong under the newly established 864.1895, not the classification regulation for general IHC reagents and kits.
5. Class II Does Not Mean Lower Technical Requirements: New Special Controls
Although the proposed rule reclassifies the products from Class III to Class II, FDA has also proposed a clear set of Special Controls requirements.
These requirements mainly focus on testing accuracy, analytical performance, clinical performance, interpretation of results, and product labeling.
5.1 Design Verification and Validation Requirements
Under the proposed 864.1895, manufacturers must provide the corresponding design verification and validation data.
| Verification item | FDA proposed requirement |
|---|---|
| Risk control measures | Identify control measures used to mitigate risks related to testing and interpretation of results, including quality controls, operating procedures, and user training requirements |
| Interpretation criteria | Define the criteria for interpreting test results, cut-off values, scoring methods, and the basis for determining positive, negative, or biomarker expression levels |
| Cut-off validation | Explain the basis for determining the cut-off value and provide validation results for samples near the clinical threshold |
| Analytical specificity | Provide studies on antigen/antibody characteristics, tissue specimen validation, cross-reactivity, cross-contamination, and endogenous and exogenous interfering substances |
| Precision and repeatability | Evaluate variation across reagent lots, operators, instruments, testing days, and readers |
| Reproducibility across sites | If the product is intended for use at multiple testing sites, provide reproducibility data across sites |
| Robustness | Evaluate the allowable ranges of key testing conditions and specimen parameters |
| Linearity | For quantitative products, provide linearity validation data covering the measuring range |
| Specimen stability | Provide stability studies for the intended specimen types, such as the stability of unstained tissue sections |
| Clinical performance | Use adequately characterized clinical specimens representative of the intended use population to demonstrate that the product performs as intended |
The following aspects deserve particular attention from manufacturers:
5.1.1 Cut-off Values and Result Interpretation
Manufacturers must define the criteria for positive and negative results, explain the basis for determining the cut-off value, and validate test performance for samples near the cut-off.
5.1.2 Precision and Repeatability
Manufacturers should not rely on results obtained under a single condition; they must also consider variation introduced by different lots, operators, instruments, testing days, and readers, based on how the product is actually used.
5.1.3 Analytical Specificity
Based on the intended use and specimen types, studies on antigen/antibody characteristics, tissue specimens, interfering substances, cross-reactivity, and cross-contamination must be conducted.
5.1.4 Clinical Performance
FDA requires representative clinical specimen data demonstrating appropriate clinical performance for the intended use.
5.2 Product Labeling Requirements
In addition to performance validation data, FDA also proposes explicit requirements for product labeling.
| Labeling content | Requirement |
|---|---|
| Summary of performance studies | Provide an appropriate summary of the performance studies conducted and their results |
| Reader qualifications | State that test results should be interpreted by qualified or appropriately trained personnel |
| Interpretation of results | State that test results must be interpreted together with other laboratory results, pathology findings, clinical information, and quality control results |
| Companion diagnostic statement | For companion diagnostic products, identify the corresponding FDA-approved oncology therapeutic product |
| Benefit and risk statement | For non-essential therapy-associated test products, explain how the test results relate to the known benefits or risks of the corresponding drug |
It is particularly important to note that the labeling of an IHC test product must be consistent with the labeling of the corresponding FDA-approved oncology therapeutic product.
6. Why Is FDA Proposing the Reclassification?
In the proposed rule, FDA’s assessment is based mainly on historical approval data, technological developments, and postmarket surveillance data.
6.1 Long-standing Approval and Use Experience
Since the first oncology therapy-associated IHC test system was approved in 1998, FDA has approved multiple related products.
As stated in the proposed rule, FDA has reviewed and approved 21 additional original PMA applications and approximately 270 related PMA supplements.
FDA believes that after long-term use, IHC technology has become relatively mature, and the testing principles and related risks are now well understood.
6.2 Evaluation Based on 14 Original PMA Applications
Under the six-year rule of section 520(h)(4) of the Federal Food, Drug, and Cosmetic Act, FDA selected 14 qualifying original PMA applications for analysis.
These applications cover five product codes, including MVC, NKF, NQF, PLS, and PKW.
Based on historical analytical performance, clinical performance, and product safety data, FDA concluded that the available evidence is sufficient to support establishing special controls.
6.3 Postmarket Adverse Event and Recall Data
FDA analyzed the MAUDE database and the medical device recall database.
As of July 15, 2026:
- A total of 48 related adverse event reports were identified;
- The reports involved product codes including PLS, MVC, PKW, QNH, and QUL;
- False negatives were the most common testing problem;
- More than 70% of the adverse event reports did not indicate a definite clinical outcome or health impact for the patient;
- One Class III recall and 10 Class II recalls were involved, with no Class I recalls.
FDA believes the existing data show that the main risks of these products can be identified and managed through appropriate special controls.
7. Do Products Already Approved via PMA Need a New 510(k)?
This is a question manufacturers should pay particular attention to in this reclassification.
The proposed rule specifically addresses the follow-up treatment of existing PMA-approved products.
Products already approved via PMA do not need to reapply under 510(k) because of this reclassification.
Specifically:
| Product situation | FDA proposed approach |
|---|---|
| Products already approved via PMA | May continue to be marketed under the original PMA approval |
| Upon formal effectiveness of this reclassification | Existing PMA products are not required to reapply under 510(k) |
| Significant changes to an approved product | For changes that could significantly affect safety or effectiveness, or major changes to the intended use, FDA expects a 510(k) to be submitted |
| Newly developed covered products | Submit a 510(k) under the new Class II classification requirements |
Therefore, this reclassification will not require existing PMA-approved products to uniformly convert their regulatory pathway.
However, if manufacturers make significant changes to their products later, they will still need to determine, based on FDA requirements, whether the changes warrant a 510(k) submission.
8. Impact on Medical Device and IVD Manufacturers
8.1 Reduced Premarket Submission Burden for Certain Oncology-Associated IHC Products
The shift from PMA to 510(k) means that, in the future, the relevant products can go through premarket review under the 510(k) pathway rather than uniformly under PMA.
8.2 More Opportunities for New Product Development and Market Entry
For manufacturers planning to develop oncology therapy-associated IHC test systems, the regulatory pathway change is expected to reduce part of the premarket approval burden.
8.3 Analytical and Clinical Performance Remain Key Review Focus
Manufacturers should not interpret this change as a removal of technical documentation requirements.
In particular, evidence will still be required for antibody specificity, testing precision, repeatability, cut-off values, clinical specimen validation, and result interpretation.
8.4 Consistency with the Corresponding Therapeutic Drug Labeling Deserves Close Attention
For companion diagnostic products, the intended use association between the test system and the corresponding FDA-approved oncology therapeutic product, as well as labeling consistency, remain important requirements.
Official documents and references
1. FDA Proposed Rule: Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product.
2. Federal Register Document No. 2026-23005.
3. Docket No. FDA-2026-N-12508.
4. 21 CFR Part 864, proposed new section 864.1895.
Original official text:
https://www.federalregister.gov/d/2026-23005
Disclaimer: This article is prepared based on the proposed rule issued by FDA on November 10, 2026. The final rule is subject to the official text published in the Federal Register. This article is for regulatory research reference only and does not constitute compliance advice.